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Abstract
Background: Prognostic and predictive significance of epidermal growth factor receptor (EGFR) in colorectal
carcinomas (CRCs) is still controversial. The aim of the present study was to explore and correlate membrane and
nuclear EGFR and cyclin-D1 protein expression with EGFR gene status of tumor cells.
Methods: Immunohistochemical and FISH analysis was performed on 135 archival formalin fixed and paraffin
embedded CRCs.
Results: Strong membrane and strong nuclear EGFR staining was detected in 16% and 57% of cases, respectively,
and strong cyclin-D1 expression in 57% samples. Gene EGFR amplification was identified in 5.9% and polysomy in
7.4% of cases, while 87% showed no EGFR gene changes. A statistically significant difference was only found
between tumor grade and expression of membrane EGFR, while nuclear EGFR and cyclin-D1 expression was not
associated with the clinicopathologic characteristics analyzed. Tumor cells displaying gene amplification and strong
protein membrane EGFR expression overlapped, while EGFR gene status showed no correlation with nuclear EGFR
and cyclin-D1. There was no association between membrane EGFR and cyclin-D1, whereas nuclear EGFR expression
was strongly related to cyclin-D1 expression.
Conclusions: Study results revealed heterogeneity among CRCs, which could have a predictive value by
identifying biologically and probably clinically different subsets of tumors with the possibly diverse response to
anti-EGFR therapies.
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Background
Colorectal cancer (CRC) is the second most common
cause of cancer-related death in developed countries, as
in the last few years the incidence has been increasing
with decreasing age at diagnosis. The 5-year relative sur-
vival rate is approximately 45%, demonstrating an
improvement from 30 years ago, when the survival rate
was 30% [1]. The irinotecan and oxaliplatin have
improved survival while the development of monoclonal
antibodies against growth factor receptors, such as
monoclonal antibodies against epidermal growth factor
receptor (EGFR), has augmented their effects [2,3].
EGFR (ErbB1) is a glycoprotein composed of an extra-
cellular ligand-binding domain, a transmembrane region,
and an intracellular tyrosine kinase domain. The recep-
tor is a member of the ErbB family of receptor tyrosine
kinases, including ErbB1, ErbB2 (HER-2), ErbB3, and
ErbB4, and it is encoded by the c-erbB protooncogene.
In normal and malignant cells, the activation of EGFR
receptor cascades has multiple consequences, such as
cell growth, differentiation, and proliferation [4,5]. Over-
expression of membrane EGFR (mEGFR) has been
found to correlate with poor prognosis in several can-
cers, including colorectal [6,7]. However, there are
results that indicate that there is an independent
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relationship between EGFR expression and CRC prog-
nosis [8,9]. Several studies have shown that EGFR levels
are a poor predictor of response to anti-EGFR therapies.
In clinical trials evaluating the efficacy of cetuximab,
treatment response was not related to the levels of
mEGFR expression [10,11]. On the other hand, current
data suggest that nuclear EGFR (nEGFR) expression
contributes to acquired resistance to cetuximab [12]. It
has been shown that mEGFR can be transported from
the plasma membrane to the nucleus. Thus, nEGFR has
two functions, first, as transcription factor it interacts
with STAT3 and E2F1 to mediate transcription of
cyclin-D1, iNOS, B-Myb and Aurora Kinase A, and sec-
ond in direct phosphorylation of the proliferating cell
nuclear antigen [13-15]. Activated cyclin-D1 controls
cell cycle, particularly in the transition from G1 to S-
phase. Despite a well-established role of cyclin-D1 in
cell cycle progression, previous data on cyclin-D1 and
clinical outcome in colon cancer have been conflicting
[16,17]. According to some studies, cyclin-D1 expression
has been associated with poor and according to others
with good prognosis, while most results revealed no
independent prognostic value of cyclin-D1 [18,19].
At the same time, membrane and nuclear EGFR
expression in CRC, according to our knowledge, has not
been published so far, and the present study was con-
ducted with the aim to explore the correlation between
mEGFR, nEGFR and cyclin-D1 expression on tumor
cells. We hypothesized that such investigation could
have predictive value by identifying biologically and
probably clinically different subsets of CRC that may
have diverse response to anti-EGFR therapies. Further-
more, the methods of tissue processing and EGFR scor-
ing systems were not homogeneous among studies, so
that reproducibility of data remains a major issue for
clinical application of the test. Therefore, our second
aim was to observe how the scoring system for EGFR
expression correlates with gene EGFR expression.
Materials and methods
Patients and tumor specimens
This retrospective study was performed on 135 archival
formalin fixed and paraffin embedded CRC tissues from
Department of Pathology, School of Medicine, Univer-
sity of Rijeka, Rijeka, Croatia, collected consecutively
from 2007 to 2009. The investigation was approved by
the Ethics Committee of the institutional review board
of the Rijeka University Hospital Center.
From the representative whole tissue samples of CRC
stained with hematoxylin-eosin (HE), the selected paraf-
fin blocks were immunohistochemically analyzed for
mEGFR. The representative areas with positive mEGFR
immunostaining were carefully selected and marked on
corresponding paraffin blocks for tissue microarray
(TMA) construction. Two tissue cores, each 2 mm in
diameter, were placed in a recipient paraffin block using
MTA Booster OI manual tissue arrayer (Alphelys, Plai-
sir, France). The final TMA blocks contained 270 cores
with tissue specimens. Normal liver tissue was used for
slide orientation. Cores were spaced at intervals of 0.5
mm in the x- and y-axes. One section from each TMA
block was stained with HE for morphological assess-
ment. Serial sections were cut from TMA blocks for
immunohistochemical staining. Five-μm thick sections
were placed on adhesive glass slides (Capillary Gap
Microscope Slides, 75 μm, Code S2024, DakoCytoma-
tion, Glostrup, Denmark), left to dry overnight at 37°C
and stored in the dark at + 4°C.
Histological grade and stage of disease were classified
according to WHO and TNM classification of Tumors
of the Colon and Rectum [20].
Immunohistochemistry and evaluation
Immunohistochemistry for mEGFR was performed on
tissue section using EGFR mouse monoclonal antibody
(IgG1 clone 2 - 18C9; pharm Dx™ ready to use kit
Dako Cytomation, Glostrup, Denmark) that recognizes
membrane EGFR in paraffin-embedded tissue (antibody
is raised against the NH2 terminus). According to the
manufacturer’s instructions, for EGFR staining we
employed antigen retrieval using proteinase K. For
cyclin-D1 we used clone SP4 (Dako Cytomation,
Glostrup, Denmark), and for nEGFR mouse monoclonal
antibody IgG1 clone EGFR.25, 1:400 (Leica Biosystems,
Newcastle Ltd., UK) (antibody is raised against the
COOH terminus and recognizes both membrane and
nuclear EGFR). Standard immunohistochemistry proce-
dure was performed on a Dako Autostainer Plus (Dako-
Cytomation, Colorado Inc, Fort Collins, CO, USA)
according to the manufacturer’s instructions, using
appropriate DakoREAL solutions (Dako, Glostrup, Den-
mark). For negative control, an irrelevant murine mono-
clonal IgG antibody was used (DakoCytomation). As
positive control for cyclin-D1 we used cervix (glandular
cervical mucosa of endocervix) and for nEGFR liver tis-
sue with positive nuclear staining of hepatocytes.
Scoring system was used for all three immunohisto-
chemical markers. With this method, the intensity of
immunohistochemical reaction and the proportion of
positive tumor cells were recorded. Membrane EGFR
was assessed according to the intensity of immunoreac-
tivity and percentage of positive tumor cells, as follows:
0, no immunoreactivity; 1, weak and incomplete stain-
ing; 2, moderate complete and basolateral membrane
immunoreactivity; and 3, strong complete and basolat-
eral membrane immunoreactivity; the percentage was
ranked as 0, negative or no immunoreactivity; 1, 1%-
25%; 2, 26%-50%; and 3, 51%-100% of neoplastic cells
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positive. The intensity of nEGFR and cyclin-D1 expres-
sion was evaluated using the following scoring approach:
0, no immunoreactivity; 1, weak brown staining nuclei
of neoplastic cells; and 2, strong brown staining nuclei
of neoplastic cells; and percentage was graded as 0,
negative or no immunoreactivity; 1, 1%-25%; 2, 26%-
50%; and 3, 51%-100% of neoplastic cells positive.
Total score was determined by adding together the
scores of staining intensity and percentage of tumor cells
showing particular membrane and nuclear staining pattern
(mEGFR, nEGFR, cyclin-D1), as follows: 0, negative immu-
noreactivity; 1-2, weak immunoreactivity; 3-4, moderate
immunoreactivity; and 5-6, strong immunoreactivity.
The evaluation of immunostaining was performed by
two pathologists (A.D. and N.J.). Accuracy of the immu-
nostaining analysis was calculated based on the interob-
server agreement of 100%. For statistical analysis, the
mean value of immunohistochemical staining of two
TMA was used.
Fluorescent in situ hybridization
The EGFR gene status evaluation was performed by
fluorescent in situ hybridization (FISH) on 3-4 μm thick
tissue sections. Tissue sections were treated using Paraf-
fin Pretreatment reagent kit (Vysis, Downers Grove,
USA) according to the manufacturer’s instructions.
Dualcolor FISH assay was performed using LSI EGFR
SpectrumOrange/CEP7 SpectrumGreen probe (Abbott,
Vysis, Downers Grove, IL, USA), which hybridizes to
the EGFR gene (orange signal) and to the centromeric
region of chromosome 7 (green signal). Briefly, TMA
sections were deparaffinized in xylene substitute, rinsed
in 100% ethanol and air dried. Subsequently, the slides
were incubated in 0.2 N HCl for 20 minutes, rinsed in 2
× SSC, pH 7.0 and immersed for 30 minutes in 1 M
NaSCN solution prewarmed at 80°C. After proteinase
digestion, slide denaturation (95°C for 5 minutes) and
hybridization (37°C overnight) were carried out in
HYBrite™(Vysis, IL, USA). On the next day, the slides
were washed, counterstained with DAPI (Vysis, Downers
Grove, IL, USA) and examined under fluorescent micro-
scope (Olympus BX50, Tokyo, Japan).
The EGFR gene assessment of in situ hybridization
was carried out by counting gene specific signals and
corresponding control signals in 20 nuclei, at two areas
of colorectal carcinoma. Overlapping or damaged nuclei
were disregarded. A cell with a normal number of
copies of the EGFR gene or chromosome 7 status was
characterized by 2 orange and 2 green signals per
nucleus. A tumor was characterized as polysomic if
there were more than two CEP7 signals per cell in more
than 40% of tumor cells or the ratio was 2.5-2.93, and
amplification of EGFR was defined as the presence of
the oncogene/centromere ratio ≥ 2.94 [21].
Statistical analysis
The data collected were statistically evaluated using the
data analysis software system STATISTICA, version 8.0
StatSoft, Inc. The categorical and counting variables
were presented by frequencies and percentages. The
possible association of variables was analyzed using
regression analysis, where correlation of variables was
presented by Spearman rank correlation coefficient. The
level of statistical significance was set at 0.05 in all
analyses.
Results
Expression of EGFR and cyclin-D1 in comparison with
clinicopathologic features in colorectal carcinoma
Among 135 CRCs analyzed for EGFR, we detected
strong membrane staining in 22 (16.3%) and strong
nuclear staining in 77 (57%) cases. Sixty-four (47.4%)
cases had moderate membrane and 49 (36.3%) moderate
nuclear staining, while 47 (34.8%) had low or undetect-
able mEGFR and 9 (6.7%) low or undetectable nEGFR
staining. In total, 135 tumor samples were examined
and classified into three cyclin-D1 expression groups.
Eight (5.9%) tumors were classified as negative or
weakly positive, 51 (36.3%) as moderate, and 76 (57%)
as strong expression samples. Finally, out of 135 tumor
samples, 8 (5.9%) showed amplification of EGFR gene,
10 (7.4%) demonstrated polysomy, and 117 (86.7%) had
no changes of the EGFR gene. The staining pattern
characteristics of tumors with mEGFR scored weak,
moderate and strong, and FISH EGFR findings are
shown in Figure 1.
The results of correlation between clinicopathologic
features, which include histologic grade of adenocarci-
noma, tumor size and stage, and immunohistochemical
markers as well as FISH outcome are summarized in
Table 1. Statistically significant difference was only
found between tumor grade and expression of mEGFR
(p = 0.042). In particular, high grade tumors were
mostly characterized with moderate mEGFR expression,
and low grade CRC with weak mEGFR expression. On
the contrary, nEGFR and cyclin-D1 expression was not
associated with the clinicopathologic characteristics ana-
lyzed. Two representative cases of low and high grade
CRC, both having strong nEGFR expression, are shown
in Figure 2.
Correlation of gene EGFR status with protein EGFR and
cyclin-D1 expression
The correlation between FISH and immunohistochem-
ical findings for EGFR gene status and protein EGFR
and cyclin-D1 expression are summarized in Table 2. As
mentioned above, no relationship was observed between
FISH results and clinicopathologic features. On the
other hand, when tissue sections used for FISH were
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compared with serial sections used for immunohisto-
chemical staining, the regions of tumor cells displaying
gene amplification and strong protein mEGFR expres-
sion overlapped (P <0.001). More precisely, most of
CRCs with EGFR gene amplification were classified in
the category with strong (5/8) and only in the minority
of cases in the category with moderate (3/8) mEGFR
immunoexpression. On the contrary, all CRCs (49/49)
with normal EGFR gene status corresponded to CRCs
with negative or low mEGFR expression, while polysomy
Figure 1 EGFR protein and gene status in colorectal carcinomas. Immunohistochemical expression of EGFR protein designated as
discontinuous, basolateral or continuous membrane staining of different intensity: (a) week, (b) moderate and (c) strong immunostainining.
Chromosome 7 copy number was analyzed in tumor cells using fluorescence in situ hybridization (FISH) with an a-satellite DNA probe for
chromosome 7 (centromere 7, red signal; EGFR gene, green signal); (d) tumor nuclei without abnormality; (e) tumor cells showed polysomy with a
greater number of red and green signals than in normal cells; and (f) tumor cells with amplification (a-c, magnification ×200, d-f magnification ×100).
Table 1 Tumor grade, size and stage in compare to immunohistochemicals markers (mEGFR, nEGFR, Cyclin D1) and
EGFR FISH in CRC
Grade pT Tumor stage
Parameters Total low high p-value 1 2 3 4 p-value 1 2 3 4 p-value
mEGFR 0.042 0.506 0.769
neg./week 49 47 2 2 35 12 0 22 4 23 0
moderate 64 54 10 0 39 23 2 22 9 33 0
strong 22 20 2 0 12 9 1 7 4 10 1
nEGFR 0.427 0.452 0.943
neg./week 9 9 0 0 6 3 0 4 2 3 0
moderate 49 44 5 2 25 20 2 15 11 22 1
strong 77 68 9 0 55 21 1 32 4 41 0
Cyclin D1 0.363 0.335 0.588
neg./week 8 8 0 0 7 1 0 4 1 3 0
moderate 51 46 5 2 24 22 3 14 11 25 1
strong 76 67 9 0 55 21 0 33 5 38 0
EGFR FISH 0.486 0.713 0.178
≤ 2.0 - 2.49 117 106 12 2 78 34 3 47 14 56 0
2.5 - 2.93 10 9 0 0 5 5 0 2 2 5 1
≥ 2.94 8 6 2 0 3 5 0 2 1 5 0




test - Spearman rank correlation coefficient
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in EGFR region was mostly (8/10) associated with mod-
erate and in rare case with strong mEGFR expression.
There was no correlation of EGFR gene status with
nEGFR and cyclin-D1 (P = 0.818 and P = 0876,
respectively).
Cyclin-D1 expression in relation to immunoexpression of
EGFR in CRC
Table 3 presents the results of statistical analysis
between immunoexpression of membrane and nuclear
EGFR and cyclin-D1 expression. There was no associa-
tion between mEGFR and cyclin-D1 (P = 0.672), while
nEGFR expression was strongly related to cyclin-D1
expression. More precisely, strong cyclin-D1 was mostly
seen in CRC with strong nEGFR (P <0.001) (Figure 3).
Figure 2 Immunohistochemical expression of nucelar EGFR (nEGFR) and cyclin-D1 in colorectal carcinoma. Low (a, b) and high (c, d)
grade adenocarcinoma with nEGFR (a, c) and cyclin-D1 (b, d) expression.
Table 2 Correlation between FISH EGFR and
immunohistochemicals markers (mEGFR, nEGFR and
Cyclin D1)
EGFR FISH
Parameters Total ≤ 2,0 - 2,49 2,5 - 2,93 ≥ 2,94 p - value
mEGFR 0.001
neg./week 49 49 0 0
moderate 64 53 8 3
strong 22 15 2 5
nEGFR 0.818
neg./week 9 9 0 0
moderate 49 42 2 5
strong 77 66 8 3
Cyclin D1 0.876
neg./week 8 7 1 0
moderate 51 45 1 5





test - Spearman rank correlation coefficient
Table 3 Immunoexpression of Cyclin D1 in relation to
EGFR in CRC
Cyclin D1
Parameters Total neg./week moderate strong p - value
mEGFR 0.672
neg./week 49 5 19 25
moderate 64 3 21 40
strong 22 0 11 11
nEGFR < 0.001
neg./week 9 6 3 0
moderate 49 1 42 6
strong 77 1 6 70




test - Spearman rank correlation coefficient
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Discussion
In previous immunohistochemical studies, there was
considerable discrepancy in the frequency and distribu-
tion of EGFR overexpression in CRC. Many of these
studies gave inconclusive information on the association
of the protein expression and clinicopathologic features
[8-11]. Furthermore, in clinical trials evaluating the effi-
cacy of cetuximab, treatment response was not related
to the levels of EGFR expression, since many patients
with EGFR expressing CRC failed to respond [10,11], or
those with EGFR negative tumor responded to therapy
[12]. Several technical reasons have supported the lack
of this association, such as prolonged storage, tissue-
fixation methods, the antibodies used, the detection
techniques and criteria used on result evaluation. In
addition, according to some authors, the possible rea-
sons for EGFR levels being a poor predictor of response
to anti-EGFR therapies include disparity between the
form or epitope of EGFR detected by immunohisto-
chemistry and the one targeted by anti-EGFR monoclo-
nal antibodies [22]. Recent emerging data suggest the
existence of a new mode of EGFR signaling pathway in
which activated EGFR undergoes nuclear translocation,
and based on in vitro study nEGFR may play a func-
tional role in the response to molecular therapeutic
agents [12]. These intriguing findings emphasize the
relevance of evaluating both the membrane and nuclear
EGFR expression in CRC in order to provide more inde-
pendent information on the protein association with
clinicopathologic features. The present study, to our
knowledge, is the first with concurrently examined
mEGFR and nEGFR expression in the same cohort of
CRC patients. The results confirmed the heterogeneity
in mEGFR and nEGFR expression without any correla-
tion between these proteins. Clinical significance of the
present findings needs further investigation.
In our study, strong mEGFR was demonstrated in less
than 20% of CRC cases, while other studies report on
EGFR overexpression in up to 82% of cases [23]. Along
with different methodologies used, other studies report-
ing a higher percentage of mEGFR expression also used
less strict criteria in defining membrane overexpression.
In the present analysis, only tumors with moderate to
strong complete membrane staining in more than 50%
of tumor cells were interpreted as strong expression,
which is probably the major cause of such a low preva-
lence of mEGFR overexpression. Strong mEGFR expres-
sion found in our study was associated with gene
amplification, found in approximately 6% of CRC sam-
ples, while moderate mEGFR was observed in those
tumors that showed chromosome 7 polysomy. The
result obtained is in agreement with studies where
EGFR amplification has been reported to correlate with
expression, although the authors stress that amplifica-
tion does not reliably predict EGFR overexpression, or
that overexpression of EGFR caused by amplification
comprised only a small portion of the cells in these
tumors [22]. The relatively low prevalence of strong
mEGFR expression (overexpression) associated with the
prevalence of EGFR gene amplification in CRC samples
supports the evaluation of immunohistochemical stain-
ing used in our study as probably being more objective.
However, in our cohort of CRCs, the strong nEGFR
expression did not correlate either with strong mEGFR
or with EGFR gene amplification, suggesting that gene
amplification is probably not a significant event that
Figure 3 Correlation between nuclear EGFR (nEGFR) and cyclin-D1 expression in colorectal carcinomas (r = 0.88, p < 0.001).
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would lead to higher nuclear translocation of the EGFR
membrane receptor, as found in breast cancer model
[24].
In comparison to clinicopathologic characteristics, the
only significant association was found between mEGFR
expression and histologic grade of CRC, or more pre-
cisely, low grade carcinomas were more characterized
with negative or weak mEGFR expression. This observa-
tion was also demonstrated in other studies, where an
association with more advanced stage, lymphovascular
invasion, and poor prognosis was also found [6,7].
Strong nEGFR expression was confirmed in more than
50% of cases and strong cyclin-D1 expression in CRC
samples was obtained in nearly the same percentage.
There are no studies on the clinical significance of
nEGFR expression in CRC, except for those referring to
the breast, oropharyngeal squamous and ovarian cancer
[14,24-26], with the expression associated with worse
prognosis [12,24,25], increased proliferation and cyclin-
D1 expression [25]. In the present study, nEGFR was
associated with cyclin-D1. The clinical significance of
these findings should be further investigated. Yet, it is
important to discuss the finding reported by Li et al.
[12] that HER family ligands are up-regulated in the
cells with acquired resistance to cetuximab. The authors
conclude that nEGFR may prove a viable molecular tar-
get, and according to our findings we presume that
these CRC could be immunohistochemically recognized.
In our study, strong cyclin-D1 expression was
observed in 57% of CRC cases. Those CRC with strong
cyclin-D1 expression showed positive correlation with
nEGFR, as also found in breast cancer [25]. According
to previous studies, increased cyclin-D1 expression
occurs in one-third of colonic tumors as an early event
during the multistage process of colon carcinogenesis
[16]. Although some studies demonstrated cyclin-D1 as
an independent indicator of poor prognosis [17], a large
cohort study suggests that cyclin-D1 expression is inde-
pendently associated with good prognosis in colon can-
cers It is very common to assume that oncogene
activation (or tumor suppressor inactivation) is asso-
ciated with aggressive tumor behavior. However, as
commented by the authors, this hypothesis does not
always hold true, since it is well recognized that MSI,
which is known to cause inactivation of a number of
tumor suppressors (including TGFBR2, BAX, and many
others), is associated with better patient outcome [27].
Conclusions
Standardized chemotherapy regimens result not only in
improved efficacy but also in an increased toxicity and
treatment costs, therefore requiring identification of
decision-making tools to select patients who are likely
to benefit from them. Both KRAS mutation and EGFR
disomy represent two negative-predictive factors able to
impair clinical responsiveness to anti-EGFR therapy with
monoclonal antibodies [28-30]; however, our findings
indicate the importance of further investigation of stan-
dardized protocols for immunohistochemical analysis of
both mEGFR and nEGFR, which will be applicable in
clinical practice.
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